Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesInnoCan Pharma Corporation

InnoCan Pharma Corporation

Consumer Defensive Household & Personal Products
PortfolioPortfolio WatchlistWatchlist
Company price
1.82 CAD 0.00(0%)
Last update at 2026-11-06T14:30:00Z
Market Cap
28.43M

Momentum Score

…

InnoCan Pharma Corporation operates as a pharmaceutical technology company in United States, Canada, Europe, and internationally. The company operates through two segments: Pharmaceuticals and Consumer Wellness. The company's Pharmaceutical segment engages in the development of drug delivery technologies for both human and animal health applications, based on advanced cannabinoids science. It offers a Cannabidiol-loaded Liposome injection Platform (LPT-CBD) that facilitates dosing and release of synthetic cannabidiol into the blood stream for the treatment of chronic pain. The company's Consumer Wellness segment engages in the development and marketing of self-care and hemp-derived cannabidiol beauty products through the brand B.I. Sky. Skincare and Beauty: Its skincare product range includes face creams, serums, masks, soaps, and neck creams for the treatment of dark spot, skin discoloration, hyperpigmentation, and anti-aging . Its pain relief products includes cannabidiol-based topical treatments, such as pain relief sprays and roll-on formulations. InnoCan Pharma Corporation was founded in 2017 and is headquartered in Calgary, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.82
Low
1.82
High
52 Week Price Range
0.15
Low
21.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

InnoCan Pharma Corporation appears positioned as a developer of cannabinoid-based therapeutics and delivery technologies, focusing on formulations intended for medical and dermatological use. Long-term growth may be supported by expansion of regulated medical cannabis markets, successful product development and licensing, and wider adoption of novel delivery platforms, which could attract partners or commercial opportunities for the company.
Primary investment risks include significant execution and financing risk from early-stage product development, regulatory uncertainty around cannabinoid therapeutics, and limited public disclosure typical of small-cap issuers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.82
Dividend Yield
-
Revenue TTM
26.61M
Revenue Per Share
5.94
Gross Profit TTM
23.93M
Debt / Equity
-
ROE
-4.47%
Net Debt
-
ROCE
-13.69%
Diluted EPS TTM
-0.34

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 0.09M 0.92M -4.03M -3.89M -10.09M
Minority interest -0.78M -1.57M -0.45M 0.12M 0.04M
Net income -1.12M -1.83M -4.70M -3.76M -10.05M
Selling general administrative 24.25M 25.89M 13.98M 6.85M 6.20M
Gross profit 23.93M 26.19M 11.98M 2.11M 0.12M
Reconciled depreciation 0.04M 0.04M 0.03M 0.04M 0.04M
Ebit - - - - -7.48M
Ebitda - - - -3.85M -10.04M
Operating income -1.25M -1.25M -3.80M -6.27M -7.48M
Interest expense 0.00M 0.01M 0.00M 0.00M 0.01M
Tax provision 0.43M 1.18M 0.21M 0.00M 0.00M
Interest income - 0.00M 0.02M 0.02M -
Net interest income -0.00M -0.01M 0.02M 0.02M -0.01M
Total revenue 26.61M 29.44M 13.66M 2.56M 0.20M
Total operating expenses 27.87M 30.68M 17.46M 8.82M 7.68M
Cost of revenue 2.68M 3.25M 1.68M 0.45M 0.07M
Total other income expense net 1.34M 2.17M -0.25M 2.36M -2.60M
Net income from continuing ops -0.34M -0.26M -4.25M -3.89M -10.09M
Net income applicable to common shares - - - - -10.05M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 10.52M 9.26M 6.94M 6.98M 12.57M
Other current assets - 0.15M 0.03M - 0.08M
Total liab 2.29M 2.24M 2.55M 0.75M 3.56M
Total stockholder equity 5.60M 5.17M 4.10M 6.39M 9.05M
Other current liab 0.39M 1.56M 1.95M 0.30M 3.08M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -36.03M -34.91M -33.07M -28.37M -24.61M
Cash 6.69M 5.01M 3.88M 4.95M 11.05M
Total current liabilities 1.35M 2.24M 2.54M 0.73M 3.56M
Property plant equipment - - - - 0.05M
Total current assets 10.44M 9.15M 6.80M 6.88M 12.52M
Net tangible assets - - - - 9.05M
Net receivables - 0.00M 0.02M 0.01M 0.17M
Long term debt 0.93M - - - -
Inventory 2.18M 3.32M 1.75M 1.13M 0.51M
Accounts payable 0.23M 0.18M 0.11M 0.10M 0.05M
Non current assets total 0.09M 0.11M 0.14M 0.10M 0.05M
Capital lease obligations 0.00M 0.01M 0.03M 0.03M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.05M -0.08M -0.03M -0.05M
Change to liabilities - - - - -0.47M
Total cashflows from investing activities - - - - -0.05M
Net borrowings 0.63M -0.02M -0.02M -0.01M -0.04M
Total cash from financing activities 1.15M 2.70M 2.92M 0.12M 15.30M
Change to operating activities - - - - 0.05M
Net income -1.12M -1.83M -4.70M -3.76M -10.05M
Change in cash 1.68M 1.12M -1.06M -6.10M 8.71M
Begin period cash flow 5.01M 3.88M 4.95M 11.05M 2.34M
End period cash flow 6.69M 5.01M 3.88M 4.95M 11.05M
Total cash from operating activities 0.49M -1.58M -3.90M -6.07M -6.63M
Issuance of capital stock 0.09M 0.89M 1.55M 0.00M 3.91M
Depreciation 0.04M 0.04M 0.03M 0.04M 0.04M
Other cashflows from investing activities - - - - -0.01M
Change to inventory 1.14M -1.57M -0.62M -0.62M -0.08M
Change to account receivables 0.00M 0.02M -0.00M -0.01M -0.47M
Other cashflows from financing activities - - - - 3.43M
Change to netincome - - - - 4.34M
Capital expenditures 0.02M 0.01M 0.05M 0.03M 0.04M
Change in working capital 1.57M -1.20M -0.79M -0.53M -0.97M
Stock based compensation 1.46M 2.01M 0.85M 0.97M 2.16M
Other non cash items - - -0.01M 0.12M -0.08M
Free cash flow 0.48M -1.59M -3.95M -6.09M -6.67M

Peer Comparison*

Sector: Consumer Defensive Industry: Household & Personal Products

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
INNO
InnoCan Pharma Corporation		 -
-%		 1.82 - - 1.07 3.71 0.57 116.00
CGII
CleanGo Innovations Inc.		 -0.01
0.80%		 1.24 - - 42.20 53.07 43.98 1.20

Profile*

InnoCan Pharma Corporation

InnoCan Pharma Corporation operates as a pharmaceutical technology company in United States, Canada, Europe, and internationally. The company operates through two segments: Pharmaceuticals and Consumer Wellness. The company's Pharmaceutical segment engages in the development of drug delivery technologies for both human and animal health applications, based on advanced cannabinoids science. It offers a Cannabidiol-loaded Liposome injection Platform (LPT-CBD) that facilitates dosing and release of synthetic cannabidiol into the blood stream for the treatment of chronic pain. The company's Consumer Wellness segment engages in the development and marketing of self-care and hemp-derived cannabidiol beauty products through the brand B.I. Sky. Skincare and Beauty: Its skincare product range includes face creams, serums, masks, soaps, and neck creams for the treatment of dark spot, skin discoloration, hyperpigmentation, and anti-aging . Its pain relief products includes cannabidiol-based topical treatments, such as pain relief sprays and roll-on formulations. InnoCan Pharma Corporation was founded in 2017 and is headquartered in Calgary, Canada.

1015, 926 ? 5 Avenue SW, Calgary, AB, Canada, T2P 0N7

516 210 4025

https://innocanpharma.com

Name Title Year Born
Ms. Iris Bincovich CEO & Interim Chairwoman 1970
Mr. Nelson Harvey Halpern F.C.A., FCPA Chief Financial Officer 1959
Mr. Roni Kamhi COO, CEO of B.I. Sky Global LTD & Director 1976
Mr. Eyal Flom L.L.M., M.B.A. Company Secretary, General Counsel & Director 1967
Dr. Eyal Kalo Vice President of Research & Development 1978

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 4.90
+11.11%
UCU
CAD 2.37
+10.75%
ANRG
CAD 1.90
+10.47%
EPRX
CAD 10.71
+10.30%
DIV
CAD 3.77
-7.37%
CSU
CAD 3281.97
-6.93%
LMN
CAD 26.62
-5.23%
TOI
CAD 99.75
-4.80%
GRZ
CAD 5.05
-4.72%

Equity Sectors*

  • Basic Materials

    +4.21%

  • Communication Services

    -0.63%

  • Consumer Cyclical

    +1.12%

  • Consumer Defensive

    +0.09%

  • Energy

    +1.91%

  • Financial Services

    +1.63%

  • Healthcare

    +1.49%

  • Industrials

    +3.56%

  • Real Estate

    +0.66%

  • Technology

    +1.84%

  • Utilities

    +1.24%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…